Real-life use of ropeg-interferon α2b in polycythemia vera: patient selection and clinical outcomes
Annals of Hematology · 2024-07 · 103 (7) · 2347-2354
DOI: 10.1007/s00277-024-05809-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 21.05.2024. Verfasst von Francesca Palandri und 13 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy. francesca.palandri@unibo.it. Hauptthemen laut MEDLINE: Polycythemia Vera, Interferon-alpha, Polyethylene Glycols, Recombinant Proteins. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alma Mater Studiorum - Università di Bologna.
Abstract (Originalsprache)
Ropeginterferon-alfa2b (ropegIFNα2b) is a long-acting IFN formulation with broad FDA/EMA approval as a therapy of polycythemia vera (PV) with no symptomatic splenomegaly. There is currently lack of information on the real-world patient selection, including the impact of local reimbursement policies, and drug management, particularly: type/timing of screening and follow-up tests; absolute/relative contraindications to therapy; ropegIFNα2b dose and combinations with hydroxyurea. As a sub-analysis of the PV-ARC retrospective study (NCT06134102), we here report our monocenter experience with ropegIFNα2b in the period from January 2021, corresponding to drug availability outside clinical trial, and December 2023. Among the 149 patients with EMA/FDA indication, only 55 (36.9%) met the local reimbursement criteria and 18 (12.1%) received ropegIFNα2b. Thanks to appropriate screening, relative/absolute contraindications to ropegIFNα2b were detected and managed in a multidisciplinary manner. Efficacy and safety of ropegIFNα2b was confirmed, with 3 cases of early molecular response. General use of low ropegIFNα2b dose, with frequent need for hydroxyurea combinations, was noted. This real-world experience suggests a significant impact of local regulations on drug prescription and the need for greater real-world data collection on ropegIFNα2b in PV patients. Also, it describes appropriate multidisciplinary screening and monitoring procedures during ropegIFNα2b therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy. francesca.palandri@unibo.it.
- Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna, Bologna, 40138, Italy.
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
- UO Interaziendale Medicina Interna ad Indirizzo Reumatologico AUSL BO-IRCCS AOUBO, Bologna, Italy.
- Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Förderung
- Alma Mater Studiorum - Università di Bologna
Zitieren
APA
Palandri, F., Branzanti, F., Venturi, M., Dedola, A., Fontana, G., Loffredo, M., Patuelli, A., Ottaviani, E., Bersani, M., Reta, M., Addimanda, O., Vicennati, V., Vianelli, N., & Cavo, M. (2024). Real-life use of ropeg-interferon α2b in polycythemia vera: patient selection and clinical outcomes. Annals of Hematology, 103(7), 2347-2354. https://doi.org/10.1007/s00277-024-05809-6
Vancouver
Palandri F, Branzanti F, Venturi M, Dedola A, Fontana G, Loffredo M, et al. Real-life use of ropeg-interferon α2b in polycythemia vera: patient selection and clinical outcomes. Annals of Hematology. 2024;103(7):2347-2354. doi:10.1007/s00277-024-05809-6
BibTeX
@article{Palandri2024,
author = {Palandri, Francesca and Branzanti, F and Venturi, M and Dedola, A and Fontana, G and Loffredo, M and Patuelli, A and Ottaviani, E and Bersani, M and Reta, M and Addimanda, O and Vicennati, V and Vianelli, N and Cavo, M},
title = {Real-life use of ropeg-interferon α2b in polycythemia vera: patient selection and clinical outcomes},
journal = {Annals of Hematology},
year = {2024},
volume = {103},
number = {7},
pages = {2347--2354},
doi = {10.1007/s00277-024-05809-6}
}
EUVIMED